I see that no one had responded back to your posting about using USP
Chapter 60 in a sterile manufacturing facility.
In the introduction of USP Chapter 60, it is stated as follows:
The tests are designed to determine whether a substance or preparation
complies with an established specification for microbiological quality
and/or to evaluate whether products—especially those for inhalation use or
aqueous preparations for oral, oromucosal, cutaneous, or nasal use—contain
members of the Bcc.
In reality, there is no reason for using USP Chapter 60 because the chapter
is for non-sterile aqueous and inhalation products based upon the
introduction of the chapter. However, it is stated in the testing product
section that it may be used for the testing of pharmaceutical waters. It
would be interesting to see if regulatory authorities would require
Water-for-Injection that is used for making sterile product formulations be
tested for the presence of Burkholderia cepacia complex by using the
methodology of this chapter by having this particular sentence in the
By having this sentence present in the chapter, I would suspect that you
would be required to conduct Burkholderia cepacia complex of collected
Water-for-Injection samples because it is kind of vague of what is meant as
pharmaceutical water in the chapter. From my perspective, the presence of
any Gram-negative bacterial species in Water-for-Injection samples would be
Donald J. English Microbiological Quality Consulting LLC
Florham Park, New Jersey 07932
On Fri, Jul 17, 2020 at 7:35 AM Berman, Alison <[log in to unmask]>
> Is anyone performing chapter <60> testing at a sterile injectable
> manufacturing company, at any stage of manufacturing?
> Is there any reason one may do so and if yes, on what would the test be
> Alison Berman, MFS
> Quality Control - Microbiology
> [AMR_Logo_for Email Signatures_19DEC]
> O 631.924.4000 ext. 379
> [log in to unmask]<mailto:[log in to unmask]> \\
> CONFIDENTIALITY NOTE: This e-mail and any attachments are confidential and
> may be protected by legal privilege. If you are not the intended recipient,
> be aware that any disclosure, copying, distribution or use of this e-mail
> or any attachment is prohibited. If you have received this e-mail in error,
> please notify us immediately by returning it to the sender and delete this
> copy from your system. Thank you for your cooperation.
> The PMFList is supported by our sponsors as a service to the scientific
> Please take a second to visit our sponsors' web sites and say thank you
> for their support of this service.
> If your company would be interested in sponsoring this community, please
> contact [log in to unmask]
> Steris - http://www.sterislifesciences.com/
> Charles River Laboratories -
> Veltek Associates, Inc - http://www.sterile.com
> Microbiologics, Inc. - http://www.microbiologics.com
> BD Industrial Media - http://www.bd.com/ds/
> Associates of Cape Cod, Inc. - http://www.acciusa.com/
> The nature of this service is to provide a medium for communication. The
> specific statements and endorsements of individuals participating in the
> discussions are not necessarily those of the PMF or the sponsors of the
The PMFList is supported by our sponsors as a service to the scientific community.
Please take a second to visit our sponsors' web sites and say thank you for their support of this service.
If your company would be interested in sponsoring this community, please contact [log in to unmask]
Steris - http://www.sterislifesciences.com/
Charles River Laboratories - https://www2.criver.com/l/60962/2020-03-27/h6jqv6
Veltek Associates, Inc - http://www.sterile.com
Microbiologics, Inc. - http://www.microbiologics.com
BD Industrial Media - http://www.bd.com/ds/
Associates of Cape Cod, Inc. - http://www.acciusa.com/
The nature of this service is to provide a medium for communication. The specific statements and endorsements of individuals participating in the discussions are not necessarily those of the PMF or the sponsors of the list.